Stroke Care

Shanghai HeartCare Medical Technology Corporation Limited, operating under the stock code 06609.HK, is a medical device company focused on the neuro-interventional field for stroke treatment and prevention. The company was established in China on June 16, 2016, and later converted into a joint stock company on December 3, 2020. A significant milestone was achieved on August 20, 2021, when the company was listed on the Main Board of The Stock Exchange of Hong Kong Limited.

The company was founded by Mr. WANG Guohui, who serves as the chairman and chief executive officer. His nearly two-decade-long career in the research, development, and commercialization of medical devices, including a significant tenure at Shanghai MicroPort Medical (Group) Co., Ltd., has been instrumental in shaping the company's direction. Co-founder Ms. ZHANG Kun, an executive Director, also brings over 20 years of experience in the medical device sector, with a background in sales, marketing, and clinical trial management.

HeartCare Medical's business is centered on the research, development, manufacturing, and sale of medical devices. Its target market is primarily mainland China, where it distributes its products to an extensive network of hospitals. The company's business model involves creating comprehensive solutions for stroke care, from treatment to prevention. For the fiscal year 2024, the company reported revenues of RMB 277.9 million, a 19.6% year-over-year increase. The firm has also projected a significant turnaround, anticipating a net profit of at least RMB 40 million for the first half of 2025.

The company has developed a broad portfolio of products for treating ischemic and hemorrhagic strokes. For ischemic strokes, the product line includes thrombectomy devices like the Captor™ thrombectomy device, aspiration catheters, and devices for treating intracranial stenosis. For hemorrhagic strokes, it offers products such as coil embolization assistant stents and flow diverter devices. The portfolio is further supplemented by vascular access devices, including distal access catheters, microcatheters, and balloon guiding catheters, providing a one-stop solution for neuro-interventional procedures. As of August 2023, the company had 21 device products approved by China's NMPA and two approved by the U.S. FDA.

Keywords: neuro-interventional devices, stroke treatment, medical technology, ischemic stroke, hemorrhagic stroke, thrombectomy, medical device manufacturing, Shanghai HeartCare Medical, Captor thrombectomy device, intracranial stenosis, embolization, vascular access devices, medical device R&D, Chinese medical market, publicly traded, HKEX:6609, stroke prevention, interventional neurology, medical instruments, catheter technology